Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Phase 1: Advanced or Refractory Solid Tumours”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT02332668
What this trial is testing

Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Who this might be right for
MelanomaLymphomaSolid Tumor+2 more
Merck Sharp & Dohme LLC 370
Early research (Phase 1)Ended earlyNCT00511576
What this trial is testing

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Who this might be right for
Breast CancerLung CancerPulmonary Cancer+5 more
Mirati Therapeutics Inc. 54
Early research (Phase 1)Study completedNCT02592785
What this trial is testing

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Neoplasms
Bayer 9
Early research (Phase 1)UnknownNCT05650580
What this trial is testing

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Who this might be right for
Non-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma RefractoryAdvanced Solid Tumor
Tarapeutics Science Inc. 26
Early research (Phase 1)Looking for participantsNCT05892718
What this trial is testing

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Who this might be right for
Advanced Solid TumorRefractory Non-Hodgkin Lymphoma
FBD Biologics Limited 80
Early research (Phase 1)Looking for participantsNCT05341557
What this trial is testing

BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Who this might be right for
Advanced Solid TumorLymphomaNSCLC+1 more
Betta Pharmaceuticals Co., Ltd. 110
Early research (Phase 1)Looking for participantsNCT05039801
What this trial is testing

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid Neoplasm+35 more
M.D. Anderson Cancer Center 54
Early research (Phase 1)Study completedNCT01346358
What this trial is testing

IMC-CS4 in Subjects With Advanced Solid Tumors

Who this might be right for
Neoplasms
Eli Lilly and Company 52
Early research (Phase 1)Study completedNCT01340040
What this trial is testing

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Who this might be right for
CancerAdvanced Solid Malignancies
AstraZeneca 10
Early research (Phase 1)Study completedNCT00207012
What this trial is testing

MAD Refractory: Solid Tumor QD w/o Break

Who this might be right for
HER2 or EGFR Expressing Advanced Solid Malignancies
Bristol-Myers Squibb 45
Early research (Phase 1)Study completedNCT00676299
What this trial is testing

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Who this might be right for
Protein Kinase InhibitorsAntineoplastic ProtocolsClinical Trial, Phase 1+4 more
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 19
Early research (Phase 1)Not Yet RecruitingNCT07779798
What this trial is testing

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

Who this might be right for
Advanced Solid TumorsRecurrent or Progressive GlioblastomaRelapse or Refractory Myeloid Malignancies
Crossbow Therapeutics, Inc. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06234098
What this trial is testing

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Who this might be right for
Solid Tumor
Alyssum Therapeutics 100
Early research (Phase 1)Study completedNCT05309187
What this trial is testing

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Who this might be right for
Solid Tumor, Adult
Immune-Onc Therapeutics 22
Early research (Phase 1)Study completedNCT03406949
What this trial is testing

MGD009/MGA012 Combination in Relapsed/Refractory Cancer

Who this might be right for
Advanced Solid Tumors
MacroGenics 25
Early research (Phase 1)Study completedNCT05187858
What this trial is testing

LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Who this might be right for
NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
Lupin Ltd. 15
Early research (Phase 1)Study completedNCT01910545
What this trial is testing

Phase 1 Study of OTS167 in Patients With Solid Tumors

Who this might be right for
Solid TumorsMetastatic Tumors
OncoTherapy Science, Inc. 32
Testing effectiveness (Phase 2)Study completedNCT01078662
What this trial is testing

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Who this might be right for
OvarianBreastProstate+2 more
AstraZeneca 298
Early research (Phase 1)Not Yet RecruitingNCT06383507
What this trial is testing

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Who this might be right for
Metastatic TumorAdvanced Solid TumorRenal Cell Carcinoma+4 more
Zhejiang University 18
Early research (Phase 1)Study completedNCT01014936
What this trial is testing

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Who this might be right for
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
EMD Serono 149
Next Page